German biotech firm Evotec plans to list on the Nasdaq under the symbol "EVO" on November 4th.
The company would look to raise up to $575.5 million in the IPO by offering 22 million American depositary shares (ADSs) at $26.16 each, according to its filing. Each ADS represents one-half of an ordinary share.
According to Reuters, Evotec SE would seek a valuation of about $9.2 billion in its initial public offering in the United States. BofA Securities and Morgan Stanley are the lead underwriters for the offering.
As of October 31st, The company has a market capitalization of $8.2 billion on the Frankfurt Stock Exchange, where its shares are already listed.
Business Overview
Founded in 1993, Hamburg-headquartered Evotec is an industry-leading drug discovery and development partner for the pharmaceutical and biotechnology industry.
It offers a suite of technologies that enable faster and cheaper drug discoveries by pharmaceutical companies.
The company last year received a grant from the Bill & Melinda Gates Foundation to help identify and develop potential monoclonal antibody drugs for the prevention of severe COVID-19.
Evotec's work to date has resulted in 11 disclosed pipeline assets in clinical development, and over 100 pipeline assets in the discovery and preclinical phase.
In the meanwhile, it has developed a broad multi-disciplinary network of collaborations with over 800 partnerships across the pharmaceutical and biotechnology industry and academia.
Evotec generate revenue through three core collaboration routes:
1)“Fee-for-service”: byproviding stand-alone or fully integrated drug discovery and development solutions to partners on a fee-for-service and FTE-rate basis;
2)EVOroyalty: by receiving milestones and royalties on assets;
3)EVOequity: through equity ownership in emerging, highly innovative companies and translational academic institutional projects.
As of June 30, 2021, it had 24 investments with 90 active projects in our EVOequity pipeline.
Financial Performance
Revenues from contracts with customers increased by 17.5%, from €231.0 million for the six months ended June 30, 2020 to €271.3 million in the six months ended June 30, 2021.
The increase is mainly due to a positive performance across all business lines as well as the higher contribution of Just – Evotec Biologics.
Net income increased by €105.5 million from €7.26 million in the six months ended June 30, 2020 to €112.71 million in the six months ended June 30, 2021. The increase is mainly resulted from the fair value adjustment of Evotec’s participation in Exscientia Ltd. in the amount of €116.1 million.
Click to view the prospectus
$Evotec (EVO.US)$

瑞恩cohen向他的20萬追隨者分享簡短的神秘tweet並不陌生。 $Twitter (Delisted) (TWTR.US)$ 周日，該公司主席再次發布了引起投資者研究的簡短tweet。 $遊戲驛站 (GME.US)$ 10月31日，cohen發送了簡單的“MGGA”tweet。
cohen這個單詞片語最有可能的解釋是四個字母代表“重新榮耀遊戲驛站”，這是對前美國總統特朗普概念的一種致敬。重新榮耀遊戲驛站，這是前總統特朗普概念作為競選口號和集會口號使用的流行首字母縮寫的一個致意。
儘管這不太可能，也許cohen正在創造自己的投資縮寫，類似於FAANG，一個熱門的科技股籃子 $Meta Platforms (FB.US)$ $蘋果 (AAPL.US)$ $亞馬遜 (AMZN.US)$ $奈飛 (NFLX.US)$ 和 $谷歌-C (GOOG.US)$ $谷歌-A (GOOGL.US)$ 曾經被稱為Google。

$CorMedix (CRMD.US)$ 閱讀他們的文件，該公司一定會很快上班到 9.00-10.00 並留下。他們本月也有 FDA 公告。藥物批准可能在 1 月之前發生。股票有可能在 3-4 個月內上漲至 25.00。在此之前，我將開始在 6.00 以下購買盡可能多的股票。將會增加 500%。約 900,000 股只有可用，直到價格高於 7 點之前。

$蘋果 (AAPL.US)$ 現在可以買嗎？